BIOGEN INC (BIIB) Stock Fundamental Analysis

NASDAQ:BIIB • US09062X1037

191.82 USD
+3.8 (+2.02%)
At close: Feb 27, 2026
187.99 USD
-3.83 (-2%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 520 industry peers in the Biotechnology industry. BIIB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BIIB is valued quite cheap, but it does not seem to be growing. This makes BIIB very considerable for value investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • BIIB had positive earnings in the past year.
  • BIIB had a positive operating cash flow in the past year.
  • BIIB had positive earnings in each of the past 5 years.
  • Each year in the past 5 years BIIB had a positive operating cash flow.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • BIIB has a Return On Assets of 4.39%. This is amongst the best in the industry. BIIB outperforms 90.42% of its industry peers.
  • With an excellent Return On Equity value of 7.08%, BIIB belongs to the best of the industry, outperforming 91.00% of the companies in the same industry.
  • BIIB has a better Return On Invested Capital (8.93%) than 93.87% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 17.87%.
  • The last Return On Invested Capital (8.93%) for BIIB is above the 3 year average (8.93%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 13.07%, BIIB belongs to the top of the industry, outperforming 91.95% of the companies in the same industry.
  • BIIB's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 27.94%, BIIB belongs to the top of the industry, outperforming 96.55% of the companies in the same industry.
  • BIIB's Operating Margin has declined in the last couple of years.
  • BIIB has a Gross Margin of 75.69%. This is amongst the best in the industry. BIIB outperforms 84.10% of its industry peers.
  • In the last couple of years the Gross Margin of BIIB has declined.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
  • Compared to 1 year ago, BIIB has more shares outstanding
  • BIIB has less shares outstanding than it did 5 years ago.
  • BIIB has a better debt/assets ratio than last year.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • BIIB has an Altman-Z score of 3.36. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
  • BIIB has a better Altman-Z score (3.36) than 67.62% of its industry peers.
  • BIIB has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as BIIB would need 3.11 years to pay back of all of its debts.
  • The Debt to FCF ratio of BIIB (3.11) is better than 92.72% of its industry peers.
  • BIIB has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • BIIB has a worse Debt to Equity ratio (0.34) than 68.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.36
ROIC/WACC1.1
WACC8.11%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • BIIB has a Current Ratio of 2.68. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • BIIB's Current ratio of 2.68 is on the low side compared to the rest of the industry. BIIB is outperformed by 68.77% of its industry peers.
  • A Quick Ratio of 2.03 indicates that BIIB has no problem at all paying its short term obligations.
  • BIIB has a worse Quick ratio (2.03) than 74.33% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for BIIB have decreased by -7.16% in the last year.
  • BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.17% yearly.
  • Looking at the last year, BIIB shows a small growth in Revenue. The Revenue has grown by 2.22% in the last year.
  • The Revenue has been decreasing by -5.96% on average over the past years.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.54% on average over the next years.
  • Based on estimates for the next years, BIIB will show a decrease in Revenue. The Revenue will decrease by -0.42% on average per year.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue Next Year-3.97%
Revenue Next 2Y-2.47%
Revenue Next 3Y-1.27%
Revenue Next 5Y-0.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.55, the valuation of BIIB can be described as correct.
  • Based on the Price/Earnings ratio, BIIB is valued cheaply inside the industry as 96.36% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.07. BIIB is valued rather cheaply when compared to this.
  • BIIB is valuated correctly with a Price/Forward Earnings ratio of 12.61.
  • Based on the Price/Forward Earnings ratio, BIIB is valued cheaply inside the industry as 97.13% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. BIIB is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 12.55
Fwd PE 12.61
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.89% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 97.32% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.94
EV/EBITDA 8.41
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOGEN INC

NASDAQ:BIIB (2/27/2026, 8:00:02 PM)

After market: 187.99 -3.83 (-2%)

191.82

+3.8 (+2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner Change4.8%
Ins Owners0.15%
Ins Owner Change7.85%
Market Cap28.15B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.33
Price Target210.39 (9.68%)
Short Float %3.2%
Short Ratio2.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)8.87%
PT rev (3m)17.24%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)-1.51%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.7%
Valuation
Industry RankSector Rank
PE 12.55
Fwd PE 12.61
P/S 2.85
P/FCF 13.94
P/OCF 12.77
P/B 1.54
P/tB 10.88
EV/EBITDA 8.41
EPS(TTM)15.29
EY7.97%
EPS(NY)15.21
Fwd EY7.93%
FCF(TTM)13.76
FCFY7.17%
OCF(TTM)15.02
OCFY7.83%
SpS67.39
BVpS124.4
TBVpS17.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number206.87
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.36
F-Score4
WACC8.11%
ROIC/WACC1.1
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y3.54%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.97%
Revenue Next 2Y-2.47%
Revenue Next 3Y-1.27%
Revenue Next 5Y-0.42%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / BIIB FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


How profitable is BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a profitability rating of 7 / 10.


How financially healthy is BIOGEN INC?

The financial health rating of BIOGEN INC (BIIB) is 7 / 10.